Table 4.

Activating and inhibitory combinations with different KIR genotypes and their HLA ligands according to the time to treatment failure (TTF ≤6 or ≥10 months).

KIR/HLA activating combinations presence	TTF ≤ 6 months	TTF ≥ 10 months	p
KIR 2DS1-HLA C2C2 or C1C2
Yes	6 (28.6%)	15 (71.4%)	p = 0.002
No	14 (77.8%)	4 (22.2%)
KIR 2DS2-HLA C1C1 or C1C2
Yes	9 (45%)	11 (55%)
No	11 (57.9%)	8 (42.1%)	p = 0.42
KIR 3DS1-HLA w4w4 or w4w6
Yes	6 (35.3%)	11 (64.7%)	p = 0.079
No	14 (63.6%)	8 (36.4%)
KIR/HLA inhibitory combinations presence	TTF ≤ 6 months	TTF ≥ 10 months	p
2DL1-HLA C2C2 or C1C2
Yes	14 (48.3%)	15 (51.7%)	p = 0.52
No	6 (60%)	4 (40%)
2DL2-HLA C1C1 or C1C2
Yes	9 (45%)	11 (55%)	p = 0.42
No	11 (57.9%)	8 (42.1%)
2DL3-HLA C1C1 or C1C2
Yes	14 (50%)	14 (50%)	p = 0.79
No	6 (54.5%)	5 (45.5%)
3DL1-HLA w4w4 or w4w6
Yes	16 (51.6%)	15 (48.4%)	p = 0.93
No	4 (50%)	4 (50%)